Home

Journal

Articles

Login
Sciences of Pharmacy
Creative Commons License
Open Access
DOAJ
Garuda
Harvard Library
OneSearch
Universiteit Leiden
Google Scholar
Index Copernicus
DRJI
WorldCat
BASE
ROAD
OAISter
ResearchBib
CiteFactor
Sciences of Pharmacy

Sciences of Pharmacy

e-ISSN 2830-7259
p-ISSN 2830-7046

Sciences of Pharmacy (SciPhar) is an international, peer-reviewed open-access journal of pharmacy. We offer a platform and place for researchers and intellectuals, especially the youth, to share their insights and works. SciPhar accepts original article, reviews, mini-review, book-review, technical note, case report, case series, clinical trial, opinion/perspective, conference proceeding, and pictorial essay. Author may submit or suggest another type of scientific manuscript.

Publication on SciPhar is free of charge at any stage. After acceptance, all papers are instantly templated and published online, with an average editorial process time of 0-3 days.

Scope
Sciphar covers all aspects of pharmacy, including but not limited to:
  • Drug discovery (pharmacognosy, drug synthesis, target identification and validation, and lead optimization).
  • Drug development (preclinical and clinical drug development, drug delivery design, pharmaceutical formulation and characterization, and stability test). 
  • Fundamental and clinical pharmacology (pharmaceutical activity and effectivity, drug mechanisms, dose studies, pharmacokinetics, pharmacodynamics, drug metabolism, and pharmacogenetics). 
  • Pharmaceuticals (gene-based, cell-based, protein-based therapy, vaccine, other drug modalities, routes of administration, drug classes, drug nomenclature). 
  • Drug toxicity and safety (drug-drug interactions, adverse drug reactions, mechanisms of drug toxicity, pharmacovigilance). 
  • Pharmacy regulation, administration, and management.
  • Pharmacoepidemiology, pharmacoeconomics, and pharmacy.

Contact us at our official email: sciphar@etflin.com

Editor-in-Chief

apt. Abd. Kakhar Umar, M.Pharm
Department of Pharmaceutics and Pharmaceutical Technology, Padjadjaran University, Indonesia
Editor Profile

Editors

Prof. Dr. apt. Marline Abdassah Bratadiredja, MS
Departement of Pharmaceutic and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
Google Scholar
Scopus ID

Prof. Dr. Moelyono Moektiwardoyo, MS., Apt.
Department of Biology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
ORCID
Google Scholar
Scopus ID
Research Gate

Prof. apt. Muhammad Sulaiman Zubair, M.Si., Ph.D.
Natural Product Research Group, Department of Pharmacy, Faculty of Science, Tadulako University, Palu 94118, Indonesia
ORCID
Google Scholar
Scopus ID
Research Gate

Assistant Prof. Jittima Amie Luckanagul, Ph.D.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
ORCID
Google Scholar
Scopus ID
Research Gate

Mustafa Azizoğlu, MD, Ph.D.
Department of Pediatric Surgery, Faculty of Medicine, Dicle University, Turkey.

ORCID

Constancy Prisca Aleru-Obogai, B.MLS., AMLSN., M.Sc., Ph.D.
Department of Medical Laboratory Science, Rivers State University of Science & Technology, Nkpolu-Oroworukwo, Port Harcourt, Nigeria.
ORCID
Google Scholar
Research Gate

Dr. dr. Cosmos Octavianus Mangunsong, SpM(K)
Indonesian Ophthalmologist Association [IOA] – PERDAMI, Jakarta, Indonesia

Dr. apt. Garnadi Jafar, M.Si
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Bhakti Kencana, Bandung City 40614, Indonesia
Google Scholar
Scopus ID

Keerthic Aswin, M.Pharm
CSIR-GATE JRF, Institute of Genomics and Integrative Biology, New Delhi, India
Google Scholar
Scopus ID
Research Gate

Marina Mikhailovna Shumkova, M.Sc. in Pharmaceutical Science
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
Apt. Dhanang Prawira Nugraha., S.Farm., M.Farm
Department of Pharmacy, Faculty of Sciences and Technology, Ma Chung University, Malang 65151, Indonesia

Google Scholar

Ernest Domanaanmwi Ganaa, M.Sc., Ph.D.
ICT department of Hilla Limann Technical University, Ghana
Google Scholar

Ebrahim Tavakoli, Ph.D.
Department of Biomedical Engineering, Faculty of Engineering, University of Isfahan, Isfahan, P.O. Box 8174613441, Iran.

ResearchGate

Flowchart of Submission Process
ETFLIN Journal Submission

Submission and Tracking of manuscript
We use a submission system which can be accessed by registering an account through the Login button (top right).

Manuscript Format
We encourage author to use this template (Download Template). All instructions are within the template and it is easy to follow.  Original Article must contain these sections: Abstract, Introduction, Experimental Section, Results, Discussion (can be combined with results), and Conclusion. For other types of manuscript, any structure is acceptable as long as it contains: Abstract, Introduction/Background, and Conclusion/Summary (a summary can be included within the discussion section).
Types of Manuscript

SciPhar accepts original article, reviews, mini-review, book-review, technical note, case report, case series, clinical trial, opinion/perspective, conference proceeding, and pictorial essay. Author may submit or suggest another type of scientific manuscript.

Manuscript Content

Font and Style
We use Segoi UI font style with font size as follows:
Title : 18 pt
Author name : 12 pt
Section/header : 12 pt
Sub section/sub header : 11 pt
Sub of a sub section : 10 pt

Content and others : 10 pt

Title

Title must be clear and represent the whole manuscript content. The maximum title's length is 3 lines in the manuscript template. No abbreviations use unless the full term is included. 

Abstract
Unstructured abstract, not more than 250 words. The abstract should briefly highlight the background, methods, results, and conclusions of the study.

Graphical abstract
The graphical abstract should flow and depict the whole research process.
Quality: Minimum 300 dpi
Although it is optional, our editor may find your graphical abstract appealing and choose it as the issue cover.

Figures
Figure must be clear and labelled. All figures must be included in the manuscript file and positioned as they are mentioned in the text for the first time. Please use bold to the figure number, for example: Figure 1. Flowchart of the methodology.
Size: Height = should fit within a single page of the SciPhar template, width = should fit within the SciPhar template
Quality: Minimum 300 dpi

File type: JPG or PNG.

Reproduction of figures
To reproduce a figure (already published in a paper in any journal) in SciPhar, copyright permission must be obtained. If a figure is reproduced without permission, it will be considered plagiarism and the authors will be asked to rectify the same. A note like 'copyright has been obtained from Einstein et al.' must be included within the Figure legend.

Tables
Tables must be created with the insert table feature of the Microsoft word. Please do not insert table as an image.

Equations
Equations must be created with the insert equation feature of the Microsoft word. Please do not insert equation as an image. Each equation must be centered and labelled with a number.

Software to reduce grammatical errors
The use of grammarly is encouraged to minimize grammatical errors. Grammarly can be downloaded, installed, and added as an add-on to the Microsoft Word document.

Reference managing software
Authors are encouraged to use software such as Mendeley, Zotero, etc. to arrange the references. Mendeley and Zotero can be downloaded and installed. Once installed, they will appear on the 'References' tab on the Microsoft Word document.

Reference Style

We accept Vancouver style.

Funding Information
Please include funding information in your manuscript if you receive one. Full name of the funding agency and the grants number must be included. 

Authorship policy
In terms of planning the study design, data analysis, statistical analysis, software, executing work, writing, and editing, a significant contribution should be made by all contributing authors such as the first author, co-authors, and corresponding authors. Authors are encouraged to get familiar with the Committee on Publication Ethics (COPE) guidelines.

Corresponding author
The corresponding author will take the responsibility of communicating with the editors from the initial submission till publication. Depending on the requirement, there may be two corresponding authors. In the case of two corresponding authors, the asterisk '*' sign should accompany their names in the manuscript and the initials of the authors should accompany their email addresses in the manuscript.

Change of authorship
During the review process, the corresponding author may request that the authorship be changed, providing appropriate reasons for the request. It is not permitted to add or remove authors once a submission has been accepted.

Plagiarism
If possible, authors are requested to submit a plagiarism report from commercial software (or from a free online server) as a supplemental data. For all types of articles, the plagiarism percentage should be kept as low as possible (maximum upper limit 15% excluding references). Even if the plagiarism percentage remains below 15%, the authors may be further asked to reduce the plagiarism to increase the authenticity of the manuscript.

Animal ethics and cell lines
Studies should be carried out keeping in mind the standard guidelines set by OECD, CPCSEA, ICH, Animal Welfare Board of India, as well as other organizations. Ethical clearance with proper documents should be obtained from the concerned authority (for example, Institutional Animal Ethics Committee) to carry out the studies. Also, sufficient details regarding the document number should be mentioned in the manuscript. 

Retraction
Retraction guidelines provided by the Committee on Publication Ethics (COPE) will be followed. A notice of retraction will be given to a paper if the findings are unreliable, unethical, plagiarized, or manipulated. To maintain integrity, the retracted paper will remain visible on the e-bulletin page. However, a notice of retraction will accompany the paper.

DOAJ
Garuda
Harvard Library
OneSearch
Universiteit Leiden
Google Scholar
Index Copernicus
DRJI
WorldCat
BASE
ROAD
OAISter
ResearchBib
CiteFactor

Dr Muhammad Fauzi (Google Scholar)
Departement of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia

Dr James H. Zothantluanga (Google Scholar)
Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh 786004, Assam, India

Dr Maria Elvina Tresia Butar-Butar (Google Scholar)
Pharmacy Study Program, College of Health Sciences Dirgahayu, Samarinda 75122, Indonesia

Dr Lalrinmawii (Google Scholar)
Medical Officer at Keitum Health & Wellness Centre under National Ayush Mission, Government of India

Dr Ratri Rokhani (Google Scholar)
Pharmacology Laboratory, Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Banyumas 53182, Indonesia

Dr Faruk Jayanto Kelutur (Google Scholar)
Department of Pharmaceutical Science and Medicinal Chemistry, Faculty of Pharmacy, Sumedang, Universitas Padjadjaran

Dr Hardika Aditama (Google Scholar)
Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia

Dr Ridho Islamie (Google Scholar)
Departemen Farmasi Klinis dan Komunitas, Fakultas Farmasi, Universitas Surabaya, Surabaya 60293, Indonesia

Dr Irma Rahayu Latarissa (Google Scholar)
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia

Dr Iksen (Google Scholar)
Departemen Farmasi, Sekolah Tinggi Ilmu Kesehatan Senior Medan,

Dr Mia Nisrina Ambar Fatin (Google Scholar)
Fakultas Farmasi, Universitas Bhakti Kencana, Bandung, Indonesia

Dr Mayang Kusuma Dewi (Google Scholar)
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia

Dr Amelia Soyata (Google Scholar)
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia

Dr Reza Pratama (Google Scholar)
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Bhakti Kencana, Cibiru 40614 Indonesia

Dr Novaliana Devianti Sagita (Google Scholar)
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Bhakti Kencana, Cibiru 40614 Indonesia

Any enquiry related to the journal, please reach us through email below. Sciences of Pharmacy editorial's email: sciphar@etflin.com

Office: Sungai Manonda Street, Duyu, Tatanga,
Palu City 94225, Indonesia.
WhatsApp: +62 82216335184
Publisher email: halo@etflin.com

Peer-review Process

After submission of a manuscript, one of the editorial members will examine the quality of the manuscript. If the manuscript falls within the journal scope and showed high quality content, the editor will assign a minimum of two reviewers for the manuscript. After peer-review, the editor will make a decision based on the reviewer comments and recommendation. The decision made by the editor will be final. The journal follows a double-blind peer-review wherein the information of reviewers and authors are blinded from each other during the entire peer-review process. Please take a look at the Manuscript Lifecycle for detailed information.

Open Access Policy

All papers published in the journal are freely accessible immediately after publication. The papers are freely available to read, shared, and reproduced in any form with proper citation to the original work. Open access is a property of individual works and community standards that will enforce proper attribution and responsible use of the published work.

Author Charges

Publishing a paper in the journal is free. The journal do not take submission fees, editorial processing charges, article processing charges, page charges, or color charges.

Licensing Terms

The journal is licensed under the Creative Commons Attribution (CC BY) 4.0 International License.

Plagiarism

Plagiarism is not tolerated in ETFLIN journals. Plagiarism is defined as the act of copying words, ideas, images, or data from another source, including your own publications, without crediting the original source. Text copied from another source must be reused between quotation marks, and the original source must be cited. If the design of a study, or the style or language of the article, was inspired by past research, it must be fully cited.

The industry standard program Turnitin is used to check all ETFLIN submissions for plagiarism. The manuscript may be rejected if plagiarism is discovered during the peer review process. If plagiarism is discovered after publication, an inquiry will be conducted and appropriate action will be taken in accordance with our policy.

Latest Articles

Clinical Trial

Randomized Open Clinical Trial to Evaluate Netratarpana Efficacy in Elderly Patients with Primary Insomnia (Anidra)

by Satyajit Pandurang Kulkarni, Pritam Chugule, Pallavi Satyajit Kulkarni
Sciences of Pharmacy; Vol 2, Issue 1; 16 January 2023

Abstract: Primary insomnia is the most prevalent health problem among the elderly in India. It is linked to musculoskeletal disorders, cardiac disorders, Chronic Obstructive Pulmonary Disease (COPD, depression, and schizophrenia. The incidence rate of primary insomnia among the elderly is 5%, and the prevalen [...] Show more.
Abstract: Primary insomnia is the most prevalent health problem among the elderly in India. It is linked to musculoskeletal disorders, cardiac disorders, Chronic Obstructive Pulmonary Disease (COPD, depression, and schizophrenia. The incidence rate of primary insomnia among the elderly is 5%, and the prevalence rate is 20% or more. With an increase in the geriatric population, this prevalence rate will increase further. In Ayurveda, Netratarpana is described as a treatment modality for insomnia, but it was not studied yet. The study aimed to evaluate the efficacy of Netratarpana in Anidra (primary insomnia). In this RCT, 70 patients with Primary insomnia were randomly divided into two groups. In group A (n=35), Netratarpana was performed for 14 days, and group B (n= 35) was given Jatamansi powder 5 g at night with buffalo milk for 14 days as a comparison. The follow-up was taken on the 7th, 14th, and 21st day. The assessment was done using the Insomnia Severity Index (ISI) with the addition of Ayurvedic parameters. A total of 49 (70%) patients have an average age of 59.3 ± 3 years. There were 50 (71.4%) males and 20 (28.6 %) females. The sleep pattern was disturbed among 7 (10%), delayed among 19 (27.1%), and disturbed and delayed among 44 (62.9%). We found both Netratarpana and Jatamansi powder are effective in inducing sleep and preventing awakening during the night with a p-value of <0.05. It can be concluded that Netratarpana is effective in managing Anidra (primary insomnia), but the stability of the results needs to be confirmed by further study. Show less...

Case Series

Hypertriglyceridemia Induced Acute Pancreatitis: A Learn from New Cases

by Ramandeep Singh, Ranjodh Jeet Singh, Satinder Kakar, Jasmeet Kaur
Sciences of Pharmacy; Vol 2, Issue 1; 05 January 2023

Abstract: An increased risk of morbidity and mortality is associated with acute pancreatitis (AP) brought on by hypertriglyceridemia (HTG). It is essential to locate the root cause as soon as possible and give those affected the attention they need. The treatment plan includes efforts to lower blood triglycer [...] Show more.
Abstract: An increased risk of morbidity and mortality is associated with acute pancreatitis (AP) brought on by hypertriglyceridemia (HTG). It is essential to locate the root cause as soon as possible and give those affected the attention they need. The treatment plan includes efforts to lower blood triglyceride levels and supportive care. HTG-induced AP has a similar clinical course to people with other types of acute pancreatitis. However, HTG-induced AP patients have significantly higher clinical severity and associated consequences. As a result, therapy and preventing sickness recurrence depend on a correct diagnosis. At the moment, there are no acknowledged standards for the treatment of HTG-induced AP. Some therapy approaches that effectively decrease serum triglycerides include fibric acids, apheresis/plasmapheresis, insulin, heparin, and omega-3 fatty acids. Following acute phase care, lifestyle modifications, including dietary and drug therapy, are essential for long-term HTG-induced AP control and relapse prevention. To create complete and efficient HTG-induced AP treatment guidelines, more study is required. Show less...

Research Article

Antibiotic Use in Diabetes Mellitus Patients with Gangrene at Abdoel Wahab Sjahranie Samarinda Hospital

by Jessy Amalia Pratama Beta, Octaviana Maria Simbolon, Maria Elvina Tresia Butar-butar
Sciences of Pharmacy; Vol 1, Issue 2; 20 October 2022

Abstract: Gangrene is one of the complications of diabetes mellitus. Along with the rising prevalence of diabetes mellitus (DM), the prevalence of gangrene and necrosis manifestations such as ulcers and infections will ascend. The selection of appropriate antibiotics is critical in infection therapy. Inapprop [...] Show more.
Abstract: Gangrene is one of the complications of diabetes mellitus. Along with the rising prevalence of diabetes mellitus (DM), the prevalence of gangrene and necrosis manifestations such as ulcers and infections will ascend. The selection of appropriate antibiotics is critical in infection therapy. Inappropriate use of antibiotics will result in antibiotic resistance. Therefore, this research aims to overview demographic, clinical characteristics, antibiotic use profiles, and antibiotic-related problems for DM patients with gangrene at the Abdoel Wahab Sjahranie Samarinda Hospital. The study was retrospective research and was conducted in July-December 2021. Twenty-one patients met the inclusion criteria, and demographic data showed that most patients were men 57% (n=11), and most age was 39-59 years (57%, n=12). The longest period of suffering from gangrene was 6-10 years (14%, n=3). The most common length of hospitalization was 8-14 days, as reported by 52 percent (n=11) of patients, and the most common duration of antibiotic use was ten days, as reported by 86 percent (n=18) of patients. A single-used antibiotic was ceftriaxone (19%, n=4) patients. The most used antibiotic combination was ceftriaxone and metronidazole (81%, n=17). Fourteen patients used antibiotics appropriately in dosage, route, and frequency. Four patients were unsuitable for the benefit of antibiotics in terms of antibiotic type, and three patients were unsuitable for antibiotic use in terms of duration of administration. Show less...

Research Article

Knowledge Level of OTC and OTC Limited Drugs Use for Self-medication in the Community of Tondo Village, Mantikulore District, Central Sulawesi, Indonesia

by Ainun Jariya, Andi Atirah Masyita, Ririen Hardani
Sciences of Pharmacy; Vol 1, Issue 2; 19 October 2022

Abstract: Self-medication is treatment without a doctor's prescription, based on the 2022 BPS, the percentage of self-medication for the people of Central Sulawesi in 2021 is 85.85%. The purpose of the study was to determine the characteristics of the community who did self-medication, minor illnesses that we [...] Show more.
Abstract: Self-medication is treatment without a doctor's prescription, based on the 2022 BPS, the percentage of self-medication for the people of Central Sulawesi in 2021 is 85.85%. The purpose of the study was to determine the characteristics of the community who did self-medication, minor illnesses that were treated with self-medication, the profile of over-the-counter (OTC) and OTC limited medicines for self-medication and the level of knowledge of these medicines use for self-medication in the community of Tondo Village. This type of research was descriptive with a sample of 386 respondents who were taken using purposive sampling. Time of data collection during August – November 2021. Based on the results, the respondents characteristics were female (52.3%) aged 26-35 (24.4%), household work (31.1%), history of high school education (46.4%). Minor illnesses that were treated using self-medication were fever (15.54%), ulcer (7.46%), cough (15.54%), flu (18.91%), diarrhea (2.85%), headache (1 .30%), and allergy (0.78%). The profiles of OTC and OTC limited drugs are limited to paracetamol for fever (33.16%), antacids for ulcers (75.70%), Komix® for coughs (28.8%), Mixagrib® for flu (36.99%), Entrostop® for diarrhea (70,00%), Ibuprofen for headaches (100%), and CTM for allergies (100%). Number of pharmacy or drug store was 61.46%. The selection of drugs were based on experience and personal/family usage history (84.46%), and the reason for self-medication was to save treatment costs (47.15%). The level of knowledge on the use of OTC and OTC limited drugs was categorized as good (75.09%). Based on the findings, we can conclude that the level of knowledge on the use of OTC and OTC limited drugs for self-medication of Tondo people is categorized as good. Show less...

Research Article

Profile of Intravenous Preparation Mixing in Patients at the Regional General Hospital's Intensive Care Unit Abdoel Wahab Sjahranie Samarinda

by Dwi Ayu Riningsih, Octaviana Maria Simbolon, Maria Elvina Tresia Butar-butar
Sciences of Pharmacy; Vol 1, Issue 2; 15 October 2022

Abstract: Compatibility is one of the quality characteristics of intravenous (IV) preparations that influences the effectiveness of patient therapy in the Intensive Care Unit (ICU). The purpose of this study was to determine the compatibility profile of IV medication formulations given to ICU patients. This p [...] Show more.
Abstract: Compatibility is one of the quality characteristics of intravenous (IV) preparations that influences the effectiveness of patient therapy in the Intensive Care Unit (ICU). The purpose of this study was to determine the compatibility profile of IV medication formulations given to ICU patients. This prospective observational research was undertaken on patients in the ICU of a private hospital in Samarinda. The data on intravenous combination of drugs were compared in this study utilizing the ASHP Injectable Drug Information literature 21st edition, Injectable drug guide, and Manual Book. Injectable Drug Mixing was published in 2009 as a resource for determining the compatibility of intravenous formulations. Using certain criteria, combinations of intravenous medicines and their solvents are classed as compatible (C), incompatible (I), and unknown (U). The ICU had 25 patients, 15 of whom were male and 10 of them were female. There is no mixing of drug compounds containing incompatible solvents. All drugs were carried out with 100% compatible solvents. The limited information related to the compatibility and stability of these intravenous preparations encourages continuous monitoring of the patient's condition and drug levels. Show less...
Top Visited Articles

We are open for collaboration in any fields to improve health systems

Please reach us on our social media below.
© 2015 - 2023 ETFLIN (Palu, Indonesia)